CTOs on the Move

intellyst Medical Communications

www.intellyst.com

 
intellyst Medical Communications is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.intellyst.com
  • 2101 S Blackhawk St Ste 240
    Aurora, CO USA 80014
  • Phone: 703.729.8964

Executives

Name Title Contact Details

Similar Companies

Avon Podiatry

Avon Podiatry is a Avon, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LakeWood Health Center

LakeWood Health Center consists of the following four divisions: care center, clinic, hospital, and public health.. They service a population of 6,000 to 9,000 people, the number fluctuating with seasonal tourism activities. LakeWood is a federally designated Critical Access Hospital. As a Catholic non-profit organization, LakeWood Health Center is located in Baudette, Minnesota, and is owned and operated by Catholic Health Initiatives of Denver, Colorado. Our staff serve the social, health and welfare needs of the residents in Lake of the Woods County; contiguous counties, Koochiching, Beltrami, and Roseau; and neighboring Canada.

georgia ovarian cancer alliance

georgia ovarian cancer alliance is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Canadian College of Neuropsychopharmacology

The Canadian College of Neuropsychopharmacology is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Clarvista Medical

ClarVista Medical` based in Aliso Viejo` California is a leading developer of innovative products to treat challenging ophthalmic conditions. In 2012 and in conjunction with series A financing` ClarVista was spun out from Prospex Medical` a medical device incubator` to pursue the development of the HARMONI™ IOL. Between 2012 and 2014` the company developed the first generation HARMONI™ system` conducted thorough first-in-human clinical study and developed a broad portfolio of intellectual property. In 2015 the company closed on a series B financing of $14M which will be used to develop the second generation HAROMONI™ system` conduct a larger feasibility clinical trial and obtain key regulatory approvals including CE mark and US IDE.